Incyte (INCY) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Incyte (INCY) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
Incyte |
19.62 Bn |
15.60 Bn |
1.17 Bn |
| Date | Value |
|---|
| Mar 31, 2026 |
1.35% |
| Dec 31, 2025 |
-29.44% |
| Sep 30, 2025 |
4.73% |
| Jun 30, 2025 |
156.00% |
| Mar 31, 2025 |
-21.37% |
| Dec 31, 2024 |
89.01% |
| Sep 30, 2024 |
123.94% |
| Jun 30, 2024 |
-362.23% |
| Mar 31, 2024 |
-15.68% |
| Dec 31, 2023 |
17.41% |
| Sep 30, 2023 |
-15.86% |
| Jun 30, 2023 |
837.88% |
| Mar 31, 2023 |
-23.74% |
| Dec 31, 2022 |
-74.76% |
| Sep 30, 2022 |
-30.14% |
| Jun 30, 2022 |
324.91% |
| Mar 31, 2022 |
-93.26% |
| Dec 31, 2021 |
210.25% |
| Sep 30, 2021 |
21.60% |
| Jun 30, 2021 |
179.17% |
